...
nvax-img

Novavax Inc, Common Stock

NVAX

NSQ

$8.82

+$0.05

(0.57%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.40B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.91M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.09
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.53 L
$23.86 H
$8.82

About Novavax Inc, Common Stock

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNVAXSectorS&P500
1-Week Return6.27%-1.8%-0.77%
1-Month Return-2.11%-3.48%0.71%
3-Month Return-28.23%-7.2%8.81%
6-Month Return-47.26%-1.54%12.32%
1-Year Return58.49%8.39%30.57%
3-Year Return-94.78%6.07%29.21%
5-Year Return115.65%44.07%91.95%
10-Year Return-92.56%106.3%196.04%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue18.66M475.60M1.15B1.60B983.71M[{"date":"2019-12-31","value":1.17,"profit":true},{"date":"2020-12-31","value":29.74,"profit":true},{"date":"2021-12-31","value":71.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":61.52,"profit":true}]
Cost of Revenue113.84M747.03M12.66M902.64M343.77M[{"date":"2019-12-31","value":12.61,"profit":true},{"date":"2020-12-31","value":82.76,"profit":true},{"date":"2021-12-31","value":1.4,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.08,"profit":true}]
Gross Profit(95.18M)475.60M1.15B696.31M639.94M[{"date":"2019-12-31","value":-8.3,"profit":false},{"date":"2020-12-31","value":41.49,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":60.74,"profit":true},{"date":"2023-12-31","value":55.83,"profit":true}]
Gross Margin(510.02%)100.00%100.00%43.55%65.05%[{"date":"2019-12-31","value":-510.02,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":43.55,"profit":true},{"date":"2023-12-31","value":65.05,"profit":true}]
Operating Expenses148.26M892.32M2.83B1.34B779.13M[{"date":"2019-12-31","value":5.23,"profit":true},{"date":"2020-12-31","value":31.5,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":47.34,"profit":true},{"date":"2023-12-31","value":27.5,"profit":true}]
Operating Income(120.58M)(416.72M)(1.69B)(644.74M)(566.51M)[{"date":"2019-12-31","value":-12058100000,"profit":false},{"date":"2020-12-31","value":-41671900000,"profit":false},{"date":"2021-12-31","value":-168657600000,"profit":false},{"date":"2022-12-31","value":-64473600000,"profit":false},{"date":"2023-12-31","value":-56651100000,"profit":false}]
Total Non-Operating Income/Expense(25.73M)(16.68M)(49.09M)(28.79M)8.58M[{"date":"2019-12-31","value":-299.83,"profit":false},{"date":"2020-12-31","value":-194.46,"profit":false},{"date":"2021-12-31","value":-572.11,"profit":false},{"date":"2022-12-31","value":-335.56,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(132.69M)(418.26M)(1.71B)(653.65M)(543.03M)[{"date":"2019-12-31","value":-13269400000,"profit":false},{"date":"2020-12-31","value":-41825900000,"profit":false},{"date":"2021-12-31","value":-171453600000,"profit":false},{"date":"2022-12-31","value":-65364700000,"profit":false},{"date":"2023-12-31","value":-54303100000,"profit":false}]
Income Taxes(2.59M)9.25M29.21M4.29M2.03M[{"date":"2019-12-31","value":-8.87,"profit":false},{"date":"2020-12-31","value":31.65,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":14.69,"profit":true},{"date":"2023-12-31","value":6.95,"profit":true}]
Income After Taxes(130.10M)(427.50M)(1.74B)(657.94M)(545.06M)[{"date":"2019-12-31","value":-13010200000,"profit":false},{"date":"2020-12-31","value":-42750500000,"profit":false},{"date":"2021-12-31","value":-174375100000,"profit":false},{"date":"2022-12-31","value":-65793900000,"profit":false},{"date":"2023-12-31","value":-54506200000,"profit":false}]
Income From Continuous Operations(132.69M)(418.26M)(1.74B)(657.94M)(548.92M)[{"date":"2019-12-31","value":-13269400000,"profit":false},{"date":"2020-12-31","value":-41825900000,"profit":false},{"date":"2021-12-31","value":-174375100000,"profit":false},{"date":"2022-12-31","value":-65793900000,"profit":false},{"date":"2023-12-31","value":-54892200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(130.10M)(427.50M)(1.74B)(657.94M)(545.06M)[{"date":"2019-12-31","value":-13010200000,"profit":false},{"date":"2020-12-31","value":-42750500000,"profit":false},{"date":"2021-12-31","value":-174375100000,"profit":false},{"date":"2022-12-31","value":-65793900000,"profit":false},{"date":"2023-12-31","value":-54506200000,"profit":false}]
EPS (Diluted)(6.13)(6.79)(23.29)(8.40)(5.53)[{"date":"2019-12-31","value":-613,"profit":false},{"date":"2020-12-31","value":-679,"profit":false},{"date":"2021-12-31","value":-2329,"profit":false},{"date":"2022-12-31","value":-840,"profit":false},{"date":"2023-12-31","value":-553,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NVAX
Cash Ratio 0.77
Current Ratio 0.93
Quick Ratio 0.93

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NVAX
ROA (LTM) -10.76%
ROE (LTM) -898.20%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NVAX
Debt Ratio Lower is generally better. Negative is bad. 1.31
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.31

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NVAX
Trailing PE NM
Forward PE 8.55
P/S (TTM) 1.59
P/B 49.52
Price/FCF NM
EV/R 0.92
EV/Ebitda NM
PEG NM

FAQs

What is Novavax Inc share price today?

Novavax Inc (NVAX) share price today is $8.82

Can Indians buy Novavax Inc shares?

Yes, Indians can buy shares of Novavax Inc (NVAX) on Vested. To buy Novavax Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NVAX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Novavax Inc be purchased?

Yes, you can purchase fractional shares of Novavax Inc (NVAX) via the Vested app. You can start investing in Novavax Inc (NVAX) with a minimum investment of $1.

How to invest in Novavax Inc shares from India?

You can invest in shares of Novavax Inc (NVAX) via Vested in three simple steps:

  • Click on Sign Up or Invest in NVAX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Novavax Inc shares
What is Novavax Inc 52-week high and low stock price?

The 52-week high price of Novavax Inc (NVAX) is $23.86. The 52-week low price of Novavax Inc (NVAX) is $3.53.

What is Novavax Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Novavax Inc (NVAX) is

What is Novavax Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Novavax Inc (NVAX) is 49.52

What is Novavax Inc dividend yield?

The dividend yield of Novavax Inc (NVAX) is 0.00%

What is the Market Cap of Novavax Inc?

The market capitalization of Novavax Inc (NVAX) is $1.40B

What is Novavax Inc’s stock symbol?

The stock symbol (or ticker) of Novavax Inc is NVAX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top